



A Guideline for Fertility Planning Regarding Pre- and Post-Exposure to Cancer-Directed or Cancer-Like Therapy for Adult Hematology/Oncology Patients

Adapted with permission from IWK Health.

Atlantic Provinces Pediatric Hematology/Oncology Network Réseau d'Oncologie et Hématologie Pédiatrique des Provinces Atlantiques

5850/5980 University Avenue, PO Box 9700,
Halifax, NS, B3K 6R8, 1-902-470-7429, 1-888-470-5888

This guideline and all related materials were reviewed and approved by provincial working groups/specialists and by a patient and family advisor working group.
See [Appendix A](#).

Production of this guideline has been made possible through collaboration and financial support from the Canadian Partnership Against Cancer Corporation and Health Canada. The views expressed herein do not necessarily represent the views of Health Canada or the Canadian Partnership Against Cancer.

APPHON/ROHPPA supportive care guidelines have been developed by appropriate Atlantic Provinces health professional specialists (physicians, pharmacists, nurses and other health professionals) using evidence-based or best practice references. Format and content of the guidelines will change as they are reviewed and revised on a periodic basis. Care has been taken to ensure accuracy of the information. However, any physician or health professional using these guidelines will be responsible for verifying doses and administering medications and care according to their own institutional formularies and policies and acceptable standards of care.

Unofficial document if printed. To ensure that this printed is the latest version, please check website apphon-rohppa.com.

TABLE OF CONTENTS

ABBREVIATIONS.....	2
BACKGROUND.....	3
GUIDING PRINCIPLES AND VALUES	3
GUIDELINES.....	3
Estimation of Infertility Risk.....	4
Fertility Preservation Options for Individuals Assigned Female at Birth (AFAB).....	6
Fertility Assessment for Individuals Assigned Female at Birth (AFAB) After Completion of Cancer-Directed or Cancer-Like Therapy	7
Fertility Preservation Options for Individuals Assigned Male at Birth (AMAB)	9
Fertility Assessment for Individuals Assigned Male at Birth (AMAB) After Completion of Cancer-Directed or Cancer-Like Therapy	9
Effect on Offspring.....	10
Costs	10
Process	11
REFERENCES	12
APPENDICES	13
Appendix A - Guideline Reviewed and Approved at the Provincial Level	14
Appendix B - Definitions	15
Appendix C - Fertility Clinics.....	16
Appendix D - Risks, Benefits and Estimated Success of Live Birth for Select Fertility Preservation Methods.....	17
Appendix E - Table 1: Cyclophosphamide Equivalent Dosing.....	18
Appendix F - Table 2: Risk of Infertility for Individuals Assigned Female at Birth	19
Appendix G - Table 3: Risk of Infertility for Individuals Assigned Male at Birth.....	20
Appendix H - Fertility Care Outline for Individuals Assigned Female at Birth	21
Appendix I - Fertility Care Outline for Individuals Assigned Male at Birth	23

ABBREVIATIONS

AFAB - Assigned Female at Birth	HCP - Health Care Provider
AMAB - Assigned Male at Birth	HSCT - Hematopoietic Stem Cell Transplant
AMH - Anti-Mullerian Hormone	IUI - Intrauterine Insemination
AOE - Acute Ovarian Failure	IVF - In Vitro Fertilization
CED - Cyclophosphamide Equivalent Dosing	IVM - In Vitro Maturation
CPAC - Canadian Partnership Against Cancer	LH - Lutenizing Hormone
FSH - Follicle Stimulating Hormone	PM - Premature Menopause
GnRH - Gonadotropin-releasing hormone	POI - Premature Ovarian Insufficiency
Gy - Gray	

BACKGROUND

Canadian data indicates that 4250 reproductive-age individuals Assigned Female at Birth (AFAB) (20-39 years old)² and 2500 individuals Assigned Male at Birth (AMAB) 20-39 years old³ are newly diagnosed with cancer in Canada each year, yet referrals to fertility specialists/clinics and fertility preservation is much lower. This is in part due to lack of knowledge and inefficiency in the current Canadian oncofertility system⁴.

Health care providers do not always have the knowledge⁵ or consistently discuss infertility risks or deliver fertility preservation information to hematology/oncology patients at risk prior to therapy that may impact fertility nor are these services always accessible⁶. Patients and survivors have indicated that they would like to be informed at the time of diagnosis, regardless of the actual risk of fertility impairment, and despite other factors, such as cost, experimental nature of interventions, and the likelihood of surviving⁷.

These cancer care guidelines aim to facilitate that discussion and process.

GUIDING PRINCIPLES AND VALUES

All patients undergoing cancer-directed therapy or cancer-like therapy have a right to¹:

1. Know the risks of potential fertility impairment from their therapy.
2. Knowledge and choice regarding fertility preservation options
3. Understand the feasibility and potential outcome of the different fertility preservation options.
4. Discuss this information prior to exposure to therapy and multiple times throughout treatment.

GUIDELINES

1. For all patients of current or future childbearing age/status, health care providers should initiate discussions about the risks to fertility and fertility preservation options with patients at multiple points: prior to the delivery of cancer-directed or cancer-like therapy, at discussion of risks of treatment, and prior to the end of treatment/beginning of survivorship. These discussions should be documented. They should be guided by the adapted Canadian Partnership Against Cancer (CPAC) prompt: "Some cancer treatments could impact fertility or reproductive health and the ability to have biological children now and in the future. I would like to speak to a healthcare professional about this."
2. If the health care provider is unable to discuss the infertility risks and fertility preservation options, a referral to an appropriate specialist is required. Patients should be provided with contact information for the local Fertility Clinic (see [Appendix C](#)).
3. Access to or wait times for a referral to discuss fertility risk and preservation should not be a factor in the decision to refer for this discussion.
4. Some patients may require immediate initiation of cancer-directed or cancer-like therapy or be too ill to undergo fertility preservation procedures. However, they should still be informed of their infertility risk and be made aware of the reason why they were not a

suitable candidate for fertility preservation interventions prior to starting therapy. These patients may still choose and benefit from being referred to a fertility specialist. This discussion must be documented. In some cases, it is possible that patients may be suitable for fertility preservation interventions at a later date and/or in survivorship.

5. For patients who can consider fertility preservation, the options must be discussed with the patient.
6. The decision to pursue fertility preservation interventions is at the discretion of the patient. The decision not to pursue fertility preservation interventions is also an option and at the discretion of the patient.
7. No patient should be excluded from consideration of discussion of fertility preservation for any reason including prognosis, socioeconomic status, or previous history of sexual reproduction.
8. During this discussion about risks of fertility impairment, the patients will be counselled as to whether they are in the low, intermediate, high, or unknown risk of infertility.
9. During the discussion about fertility impairment and potential fertility preservation options, the patient must be made aware of the associated risks, benefits, and estimated rates of success for a live birth without or with different fertility preservation options (see [Appendix D](#)). It should be noted that each patient will have a different level of urgency to start cancer-directed and cancer-like therapy, depending on the type of cancer/other diagnosis necessitating cancer-related or cancer-like therapy and its presentation.
10. During the initial discussion about risks of fertility impairment, the patient should be made aware of costs for fertility preservation procedures, including initial banking costs, subsequent storage costs, and costs of using stored materials for in vitro fertilization. These costs are best provided in consultation with local fertility clinics; see [Appendix C](#).
11. During discussion regarding fertility preservation, it is not permissible to provide false hope that viable offspring will occur in those with low risk of fertility impairment who do not pursue fertility preservation as there are many confounding factors. Consideration should be given in case of a failed first-line cancer treatment.
12. A full discussion regarding contraceptive methods based on the teratogenicity or potential teratogenicity of cancer-directed or cancer-like therapy during and immediately following therapy should take place and revisited during the cancer care continuum.
13. Any patients who may have genetic risk factors related to their cancer diagnosis are entitled to a discussion and referral to appropriate genetic testing.

Estimation of Infertility Risk

1. Estimating the risk of infertility following cancer-directed or cancer-like therapy depends on several factors including the disease, stage, site, cumulative treatment dose, and type of chemotherapy, dose of radiation therapy, type of surgery, patient age, gender, family

history, and potentially pre-existing issues which may affect fertility. Given that many cancer treatment plans involve a combination of chemotherapy, radiation and/or surgery, estimating the true risk for individual patients is challenging.

2. The risk of infertility in this document is graded broadly as low-risk (<20%), intermediate-risk (20-80%), and high-risk (>80%). This wide range is applied due to individual variations between patients that are not fully understood, multimodal therapy, and different mechanisms of therapies on fertility. Furthermore, this risk assessment is meant to give the provider more information about their patient's treatment and expected outcomes with regard to fertility impairment. Although estimation of impaired fertility can be helpful information, this should NOT be used to make decisions about offering fertility preservation, as each patient may have their own reasons for desiring to pursue or forgo fertility preservation that is independent of the risk of fertility impairment.
3. Chemotherapy: Gonadotoxic alkylating chemotherapy agents are often categorized in terms of cyclophosphamide equivalent dosing (CED) as shown in Table 1 ([Appendix E](#)). A CED of > 4000 mg/m² is associated with a significant risk of infertility⁸. This is often the case in patients receiving chemotherapy for sarcomas or hematopoietic stem cell transplant (HSCT). Note: in individuals Assigned Male at Birth (AMAB), spermatogenesis is impaired at a lower CED than testosterone. An online calculator to determine CEDs is available at <https://fertilitypreservationpittsburgh.org/fertility-resources/fertility-risk-calculator>.
4. Other forms of systemic therapy such as tyrosine kinase inhibitors, mTOR inhibitors, and monoclonal antibodies have an unknown risk to fertility. Hormone therapy can also impact fertility. Therefore, patients receiving these agents should also be provided with information on possible infertility and fertility preservation.
5. Radiation
 - a. Individuals Assigned Female at Birth (AFAB): Radiation to the pelvis in AFAB individuals increases the risk of infertility.
 - b. Individuals Assigned Male at Birth (AMAB): Radiation to the testes and pelvis has the potential to impact both fertility and testosterone production. Data from children, adolescents, and young adults indicates that sterility is highly likely if the dose to the testes is above 6 Gy, and testosterone production is at risk if dose to the testes is above 12 Gy.
 - c. AFAB and AMAB individuals: Radiation to the hypothalamic-pituitary-axis is associated with an increased risk of subfertility or infertility, especially in doses exceeding 30 Gy. Total body irradiation also increases the risk.
6. Surgery
 - a. AFAB individuals: Bilateral oophorectomy and/or hysterectomy will result in loss of fertility and/or the ability to carry a child. It will also result in early menopause which can have impact on quality of life. Oophoropexy and unilateral oophorectomy may impact fertility as well.
 - b. AMAB individuals: Orchiectomy (unilateral), retroperitoneal lymph node dissection, major pelvic surgery, spinal or para-spinal surgery (especially low- lumbar/sacral), prostatectomy, cystectomy may affect fertility. Bilateral orchiectomy will result in loss of

fertility. It will also impact on future testosterone production which impacts sexual function.

c. Both genders: Hypothalamic-pituitary-axis surgery can affect fertility.

7. Chronic graft versus host disease of genital tissues may also impact fertility.
8. Adjuvant medications may be prescribed for several years in some cancers such as breast cancer. While taking these medications natural conception is not recommended and contraception should be used to prevent pregnancy. Some medications might have unknown risks of teratogenicity (e.g. biologic agents).
9. A summary of the risk of fertility impairment in AFAB individuals with some agents is summarized in Table 2 ([Appendix F](#)). Fertility impairment results due to premature ovarian insufficiency (POI) which can lead to acute ovarian failure (AOF) or premature menopause (PM). POI refers to AFAB individuals experiencing ovarian failure before age 40 years and can result from both chemotherapy and radiation therapy. AOF is a permanent loss of ovarian function within 5 years of cancer treatment and commonly associated with full abdominal or pelvic radiation or HSCT and can occur with chemotherapy.
10. A summary of the risk of fertility impairment in AMAB individuals with some agents is summarized in Table 3 ([Appendix G](#)).

Fertility Preservation Options for Individuals Assigned Female at Birth (AFAB)

Fertility preservation options for AFAB individuals include ovarian transposition, conservative gynecologic surgery, radiation sparing approaches, ovarian suppression therapy, oocyte cryopreservation, and ovarian tissue cryopreservation and transplantation^{9,10}.

1. Ovarian Transposition (Oophoropexy)
For patients undergoing pelvic radiation, surgically moving the ovaries out of the field may provide some benefit. However, due to radiation scatter, ovarian transposition does not always protect the ovaries and patients should be advised of the possible lack of success regarding the procedure. There is also controversy regarding the efficacy of this procedure. If performed, it should be done as close to the time of radiation treatment onset due to the risk of remigration of the ovaries. There is risk to the blood supply of the ovary during this procedure.
2. Conservative Gynecological Surgery
This is a strategy utilized to spare fertility by performing less radical surgeries with the intent of sparing as much of the reproductive organs as possible¹. It is possible that this strategy may impact the chances of successful cancer therapy or may increase the risk of disease recurrence. The principle of initial cancer therapy is to cure the patient of their cancer, and if there is cancer recurrence there is almost always a higher risk of treatment failure, death and subsequent infertility secondary to salvage therapy. This must be discussed with the patient.
3. Radiation Sparing Approaches
This will involve treating the smallest possible volume and shielding of the gonadal regions during radiation therapy to reduce scatter radiation and ovarian damage.

4. Ovarian Suppression Therapy

Using gonadotropin-releasing hormone (GnRH) analogs does not guarantee gonadal protection. The primary purpose of this is to prevent heavy menstrual bleeding during cancer therapy.

Possible benefit to reduce risk of ovarian insufficiency by reducing gonadotoxicity through hypogonadism and decreased utero-ovarian perfusion^{1,22}. This should not be the primary indication for use.

5. Oocyte Cryopreservation

Given the time required, logistics (hormonal stimulation of ovulation, transvaginal ultrasounds, oocyte harvesting) and financial cost to the patient, many patients will be unable to avail of this procedure prior to initiation of therapy. However, all patients at risk for AOF should be offered consultation with a reproductive specialist as post-therapy fertility preservation may not be feasible. Those at risk for POI may also wish to pursue oocyte cryopreservation after completion of chemotherapy if ovarian reserve remains sufficient post-treatment.

6. Ovarian Tissue Cryopreservation and Transplantation

Ovarian tissue cryopreservation and future re-implantation is an option to restore ovarian function for patients who are unable to cryopreserve oocytes for any reason. Although ovarian tissue cryopreservation is no longer considered 'experimental', it is not performed routinely in most centres and is considered on a case-by-case basis in Atlantic Canada.

There is a real concern with reintroducing cancer cells with re-implantation of ovarian tissue and it is considered a contraindication in patients with leukemia¹². There is a theoretical risk that the same re-implantation of cancer may occur with other tumors that have metastatic potential. In the future, there may be methods for using cryopreserved ovarian tissue without re-implantation into a patient, such as in vitro maturation (IVM) of oocytes, these techniques are the subjects of ongoing research.

Ovarian tissue retrieval is typically done via laparoscopy and will require additional procedure time and cost.

For AFAB patients who would like to discuss further or consider oocyte cryopreservation or ovarian tissue cryopreservation and transplantation, an algorithmic approach is outlined in [Appendix H: Fertility Care Outline for Individuals Assigned Female at Birth](#). This algorithm also outlines exclusion criteria for these 2 methods which include: urgent need to begin cancer therapy, patient too ill requiring inpatient medical care, platelet count less than $50 \times 10^9/L$ or ANC $<0.5 \times 10^9/L$, or patient unable to commit to the process.

Fertility Assessment for Individuals Assigned Female at Birth (AFAB) After Completion of Cancer-Directed or Cancer-Like Therapy

Once a patient has completed their planned therapy, an assessment should be conducted if the patient is interested or when they are considering conceiving. To note, some patients at risk of developing gonadal dysfunction/infertility may have a window for fertility preservation. It is

important that these patients be identified and offered referral to a fertility specialist to consider fertility preservation options as appropriate.

1. Medication use, especially hormonal therapies, and contraception.
2. Assessment of sexual function.
3. Hormone screening including FSH, LH, and Estradiol (on days 2-4 of the menstrual cycle). FSH, LH, and estradiol levels cannot be accurately measured while an AFAB individual is taking hormone-releasing birth control (such as oral contraceptives or hormone-releasing intrauterine devices).
4. Anti-mullerian hormone (AMH) levels can be offered and drawn in any AFAB individual at risk of infertility and are not affected by exogenous hormone replacement. The cost of testing for AMH levels may not be covered by provincial medical insurance for at-risk survivors and may be ordered by any endocrinologist or fertility specialist with a potential cost to the patient for this test.
5. A referral to the following specialists should be considered, as necessary:
 - a. Endocrinology for hypogonadism. Patients with infertility or subfertility caused by central hypogonadism may wish to discuss hormonal options for fertility purposes. In the event wait times are high for endocrinology, referrals may be directed to fertility specialists.
 - b. Gynecology for peri-menopausal symptoms (some fertility specialists manage this as well).
 - c. Reproductive gynecology for fertility preservation counseling or infertility assessment. For patients at risk of POI, decisions regarding oocyte cryopreservation or ovarian tissue cryopreservation with transplantation may be informed by declining levels of anti-mullerian hormone, declining oocyte reserve by ultrasound, or evidence of early menopause based upon history and hormonal lab values.
6. Cancer-directed or cancer-like therapy, can affect gonadal function as well. It is important this late side effect is included in post-treatment assessments.
7. For patients who had the opportunity to utilize fertility preservation technology prior to cancer-directed or cancer-like therapy, discussions regarding utilization and ongoing storage should be had.
8. Discussion should be offered yearly in follow-up after completion of cancer-directed or cancer-like therapy or when treatment plans change or evolve, as well as if pregnancy is being considered. The discussions should continue throughout survivorship.

Fertility Preservation Options for Individuals Assigned Male at Birth (AMAB)

The options for fertility preservation for AMAB individuals include:

1. Radiation Sparing Approaches
This will involve treating the smallest possible volume and shielding of the gonadal regions during radiation therapy to reduce scatter radiation and testicular damage.
2. Surgical Conservative Approaches
This is a strategy utilized to spare fertility by performing fewer radical surgeries with the intent of sparing as much of the nerves and reproductive organs as possible. For example, nerve sparing retroperitoneal lymph node dissection or partial orchiectomy in patients with only one testicle.¹ It is possible that this strategy may impact the chances of successful cancer therapy or may increase the risk of disease recurrence. The principle of initial cancer therapy is to cure the patient of their cancer, and if there is cancer recurrence there is almost always a higher risk of treatment failure, death, and subsequent infertility secondary to salvage therapy. This must be discussed with the patient.
3. Ejaculated Sperm Cryopreservation
This involves obtaining a semen sample from the AMAB individual. This can be arranged relatively quickly (within 24-48 hours) as long as the patient is in Halifax Regional Municipality or near the city of Moncton. Patients outside of Halifax or Moncton will need to travel to the clinic area.
4. Testicular Sperm Extraction
In individuals who are unable to produce a sample by masturbation and ejaculation, a testicular biopsy to extract viable sperm is an option.

For AMAB patients who would like to discuss further or consider sperm cryopreservation, referral to a local fertility clinic (see [Appendix C](#)) is required as outlined in [Appendix I](#).

Fertility Assessment for Individuals Assigned Male at Birth (AMAB) After Completion of Cancer-Directed or Cancer-Like Therapy

Once a patient has completed their planned therapy, an assessment should be conducted if the patient is interested or when they are considering conceiving. To note, some patients at risk of developing gonadal dysfunction/infertility may have a window for fertility preservation. It is important that these patients be identified and offered referral to a fertility specialist to consider fertility preservation options as appropriate.¹³

1. After completion of cancer-directed or cancer-like therapy, semen analysis testing should be offered to survivors. This testing can be arranged through their oncology team, family physicians, or local fertility clinics (see [Appendix C](#)) depending on the clinical scenario
2. The earliest time that semen analysis should be completed is 1-2 years post completion of chemotherapy. However, note that even if negative at the first testing, resumption of spermatogenesis can occur up to 10 years post-chemotherapy.
3. AMAB individuals who do not sperm bank prior to treatment and are at risk for future gonadal

toxicity should be offered a referral to reproductive endocrinology for counseling, assessment, and possible sperm banking at a local fertility clinic; see [Appendix C](#).

4. For patients with declining testosterone levels and/or rising FSH and LH levels, there may be a potential window for successful sperm banking prior to initiating exogenous testosterone replacement. Exogenous testosterone should not be initiated unless patients understand that starting testosterone will render them sterile, and reversing its effects down the road is not guaranteed. If these patients have low sperm count, they should consider sperm cryopreservation prior to starting exogenous testosterone.
5. Cancer-directed or cancer-like therapy, can affect gonadal function (semen parameters, testosterone, LH) as well. It is important this late side effect is included in post-treatment assessments.
6. For patients who had the opportunity to utilize fertility preservation technology prior to cancer-directed or cancer-like therapy, discussions regarding utilization and ongoing storage should be had.
7. Additional discussions and/or referrals may be offered yearly in follow-up after completion of cancer-directed or cancer-like therapy or when treatment plans change or evolve, as well as if pregnancy is being considered. The discussions should continue throughout survivorship.

Effect on Offspring

Children born to individuals Assigned Male at Birth (AMAB)¹⁴ or Assigned Female at Birth (AFAB) who received chemotherapy alone are expected to have similar risks of congenital abnormalities whether conception occurred naturally or through assisted reproductive technologies.

AFAB individuals treated with pelvic radiation have a higher risk of stillbirth or miscarriage, neonatal death, and having offspring who are premature, have low birth weight and are small for gestational age.

Costs

All sperm, oocyte and ovarian tissue cryopreservation will take place at a local fertility clinic (see [Appendix C](#)).

It is important to note that there are currently no reimbursement mechanisms for ongoing yearly storage fees or subsequent use of oocytes or semen for artificial reproductive techniques and these fees will be the responsibility of the patient. Private drug plans and provincial funding will sometimes cover the cost of medications related to oocyte cryopreservation and fertility treatments.

Costs for initial banking of sperm or oocytes may be partially reimbursed in select cases and discussion with the oncology team or local fertility clinics (see [Appendix C](#)) may provide the most up to date information. Fertile Future through their Power of Hope cost reduction program can assist some individuals Assigned Male at Birth (AMAB) (fertilefuture.ca/programs/cost-

[reduction-program-for-men](#)).

For some patients, the cost of fertility preservation is prohibitive. During or after the disclosure, the patient should be offered relevant educational material about fertility preservation to consider and given the opportunity to ask questions.

Process

1. Access to or wait times for a referral to discuss fertility risk and preservation should not be a factor in the decision to refer for this discussion.
2. The referral process should be as seamless and automatic as possible.

REFERENCES

1. Oktay K, Harvey BE, Partridge AH, et al. Fertility preservation for patients with cancer: American Society of Clinical Oncology clinical practice guideline update. *Journal of Clinical Oncology* 2018; 36(19): 1994-2001.
2. Yee S, Buckett W, Campbell S, et al.. A national study of the provision of oncofertility services to female patients in Canada. *J Obstet Gynaecol Can.* 2012;34:849–58
3. Yee S, Buckett W, Campbell S, Yanofsky RA, Barr RD. A national study of the provision of oncology sperm banking services among Canadian fertility clinics. *Eur J Cancer Care (Engl)* 2013.
4. <https://www.partnershipagainstcancer.ca/news-events/news/article/fertility-challenges-burden-adolescents-young-adults-cancer/>
5. Yee S, Fuller-Thomson E, Lau A, Greenblatt EM. Fertility preservation practices among Ontario oncologists. *J Cancer Educ.* 2012;27:362–8.
6. Ronn R and Holzer HEG. Oncofertility in Canada: an overview of Canadian practice and suggested action plan. *Curr Oncol*; 2013;20(5):e465-e474.
7. Patel P, Kohn TP, Cohen J, et al. Evaluation of Reported Fertility Preservation Counseling Before Chemotherapy Using the Quality Oncology Practice Initiative Survey. *JAMA Netw Open* 2020;3(7):e2010806.
8. Green DM, et al. (2014) The cyclophosphamide equivalent dose as an approach for quantifying alkylating agent exposure: a report from the Childhood Cancer Survivor Study. *Pediatric Blood & Cancer* 61(1):53-67.
9. Rodriguez-Wallberg KA, Oktay K. Fertility preservation during cancer treatment: clinical guidelines. *Cancer management and research* 2014; **6**: 105.
10. Lange S, Tait D, Matthews M. Oncofertility: an emerging discipline in obstetrics and gynecology. *Obstetrical & gynecological survey* 2013; **68**(8): 582-93.
11. Hickman LC, Llarena NC, Valentine LN, Liu X, Falcone T. Preservation of gonadal function in women undergoing chemotherapy: a systematic review and meta-analysis of the potential role for gonadotropin-releasing hormone agonists. *Journal of assisted reproduction and genetics* 2018; **35**(4): 571-81.
12. Senapati S, Morse CB, Sammel MD, et al. Fertility preservation in patients with haematological disorders: a retrospective cohort study. *Reproductive biomedicine online* 2014; **28**(1): 92-8.
13. Long-Term Follow-Up Guidelines for Survivors of Childhood, Adolescent and Young Adult Cancers. Version 5.0. 2018.
14. Ståhl O, Boyd HA, Giwercman A, et al. Risk of birth abnormalities in the offspring of men with a history of cancer: a cohort study using Danish and Swedish national registries. *Journal of the National Cancer Institute* 2011; **103**(5): 398-406.
15. Magnusson Å, Källen K, Thurin-Kjellberg A, Bergh C. The number of oocytes retrieved during IVF: a balance between efficacy and safety. *Human reproduction* 2018; **33**(1): 58-64.
16. Doyle JO, Richter KS, Lim J, Stillman RJ, Graham JR, Tucker MJ. Successful elective and medically indicated oocyte vitrification and warming for autologous in vitro fertilization,

with predicted birth probabilities for fertility preservation according to number of cryopreserved oocytes and age at retrieval. *Fertility and sterility* 2016; **105**(2): 459-66. e2.

17. Cobo A, García-Velasco J, Domingo J, Pellicer A, Remohí J. Elective and Onco-fertility preservation: factors related to IVF outcomes. *Human Reproduction* 2018; **33**(12): 2222-31.

18. Daudin M, Rives N, Walschaerts M, et al. Sperm cryopreservation in adolescents and young adults with cancer: results of the French national sperm banking network (CECOS). *Fertility and sterility* 2015; **103**(2): 478-86. e1.

19. Neal MS, Nagel K, Duckworth J, et al. Effectiveness of sperm banking in adolescents and young adults with cancer: a regional experience. *Cancer* 2007; **110**(5): 1125-9.

20. Dohle GR. Male infertility in cancer patients: review of the literature. *International journal of urology* 2010; **17**(4): 327-31.

21. Koustenis E, Pfitzer C, Balcerek M, et al. Impact of cranial irradiation and brain tumor location on fertility: a survey. *Klinische Pädiatrie* 2013; **225**(06): 320-4.

22. Blumernfeld Z. Fertility Preservation Using GnRH Agonists: Rationale, Possible Mechanisms, and Explanation of Controversy. *Clin Med Insights Reprod Health*. 2019;13:1-13.

APPENDICES

Appendix A	Guideline Reviewed and Approved at the Provincial Level
Appendix B	Definitions
Appendix C	Fertility Clinics
Appendix D	Risks, Benefits and Estimated Success of Live Birth for Select Fertility Preservation Methods
Appendix E	Table 1: Cyclophosphamide Equivalent Dosing
Appendix F	Table 2: Risk of Infertility for Individuals Assigned Female at Birth
Appendix G	Table 3: Risk of Infertility for Individuals Assigned Male at Birth
Appendix H	Fertility Care Outline for Individuals Assigned Female at Birth
Appendix I	Fertility Care Outline for Individuals Assigned Male at Birth

Appendix A - Guideline Reviewed and Approved at the Provincial Level

Guideline Working Group:

Tamara MacDonald, Guideline Lead
Carol Digout
Sarah Keeping
Toni Leamon

Rachel Sarty
Kim Vriends
Joanne Albrecht

Expert / Provincial Working Group Members:

New Brunswick:

Dr. Grlica Bolesnikov
Dr. Eshwar Kumar

Dr. Maude Landry
Dr. Samuel Jean

Nova Scotia:

Donna Boyd
Carolyn Fifield
Leslie Hill
Dr. Janice Howes

Mandy Nicholson
Dr. Jesse Ory
Melissa Paruch
Dr. Mike Ripley

Dr. Lori Wood
Ruobing Zhi

Prince Edward Island:

Michelle Barton
Julie Biso
Dr. Jessica Corbett

Marla Delaney
Denise Lockhart
Kara McQuaid-Duffy

Holly Paynter
Jenneca Pomeroy

Patient and Family Advisor Working Group:

Vin Albert
Jessica Burke*
Grace Disney
Emily Gallant*
Marianne Gonzales
Kelsey Hamilton*
Jenn Hood*

Cameron Hunt*
Erin Lucas
Carla MacKay*
Idah Nkatha
Sydney Penney*
Connor Poplar
Nicole Poplar*

Michael Rumsby*
Charlotte Russell*
Gwenyth Schulze
Veltrup*
Gabriele Sims*
Kyla Wight*
Robyn Wood*

We are grateful to those named above and the many additional members of the Patient and Family Advisor Working Group who preferred to remain anonymous.

*These patient and family advisors also participated in their respective province's Working Group or the Atlantic Steering Committee.

Appendix B - Definitions

Cancer-directed therapy - Any treatment that is given to modify, control, remove or destroy primary or metastatic cancer tissue is cancer-directed treatment.

Cancer-like therapy – Treatments that are traditionally called chemotherapy agents which may also be used to treat non-malignant conditions.

Hematopoietic stem cell transplant (HSCT) - Involves the intravenous infusion of autologous or allogeneic stem cells collected from bone marrow, peripheral blood, or umbilical cord blood to reestablish hematopoietic function in patients whose bone marrow or immune system is damaged or defective. In most cases, HSCT is completed after an intensive dose of chemotherapy called a conditioning regimen in order to allow the patient to accept the new stem cells.

Fertility preservation - The effort to help cancer patients retain their fertility or utilize treatment options or procedures to maximize future fertility success.

Ovarian transposition (Oophoropexy) – A surgery that moves your **ovaries** out of the field of radiation.

Gy- Gy is the abbreviation for gray, a unit of measurement for absorbed dose of radiation. It represents the amount of energy deposited per unit mass of a substance or tissue when exposed to ionizing radiation. One gray (Gy) equals one joule of energy absorbed per kilogram of matter (1 J/kg). Radiation therapy treatments often specify doses in grays.

Assisted reproduction – Techniques used to treat infertility or subfertility. It includes fertility treatment techniques that manipulate a AFAB individual's egg and/or an AMAB individual's sperm to improve the likelihood of pregnancy.

Subfertility - A delay in conceiving. In subfertility, the possibility of conceiving naturally exists, but takes longer than average.

Infertility –The inability to conceive naturally after one year of trying. In infertility, the likelihood of conceiving without medical intervention is unlikely.

Acute ovarian failure – Loss of ovarian function during or shortly after completion of cancer therapy. If a patient never menstruates or they cease to menstruate within 5 years after cancer diagnosis is considered as AOF.

Premature ovarian insufficiency - When an AFAB individual's ovaries stop ovulating and producing estrogen before she is 40years old.

In vitro fertilization - A medical procedure whereby an egg is fertilized by sperm outside the body.

Appendix C - Fertility Clinics

Province	Fertility clinics closest to each region
Newfoundland & Labrador	Newfoundland and Labrador Fertility Clinic 103 - 35 Major's Path, St. John's NL Phone: 709-777-7444, Fax: 709-752-3648 Newfound Fertility and Reproductive Services 1 Paton Street, St. John's NL 709-753-7611; 1-833-333-1715 Physicians at NLFS will refer patients if they require egg or embryo freezing. Patients should not self-refer and oncologist/surgeons/hematologist should refer to this clinic or call switchboard to speak to one of the fertility specialists directly. Patients can be referred to any Health Canada approved Canadian clinic. The most common clinics to which referrals are made include: Atlantic Fertility 213 - 1535 Dresden Row, Halifax NS atlanticfertility.ca Ottawa Fertility Clinic (OFC) 100 - 955 Green Valley Crescent, Ottawa ON conceive.ca
New Brunswick	Conceptia 31 Providence St. 4th floor, Pavillon Hotel-Dieu, Moncton, NB conceptia.ca
Nova Scotia	Atlantic Fertility 213 - 1535 Dresden Row, Halifax NS atlanticfertility.ca
Prince Edward Island	Atlantic Fertility 213 - 1535 Dresden Row, Halifax NS atlanticfertility.ca Conceptia 31 Providence St. 4th floor, Pavillon Hotel-Dieu, Moncton, NB conceptia.ca

Appendix D - Risks, Benefits and Estimated Success of Live Birth for Select Fertility Preservation Methods

Item	Risks	Benefits	Estimated Success of LiveBirth
Fertility Preservation for Individuals Assigned Female at Birth (AFAB) via Oocyte Cryopreservation	1) IVF stimulation phase lasts 9-11 days and is associated with daily subcutaneous injections of gonadotropins and GnRH antagonists. Monitoring is required with transvaginal ultrasound and bloodwork every 2-3 days. 2) Egg retrieval occurs via a transvaginal probe and requires conscious sedation. 3) Unknown if the delay may impact cancer outcomes in some cases. 4) Long term storage issues, risk of storage failure, and ethical considerations if the patient passes away. 5) Social discomfort in some cases with discussing oocyte cryopreservation.	1) Option to potentially preserve fertility in cases of impairment. 2) Self-reassurance if successful oocyte retrieval	1) It is estimated that per collection patients will freeze 5-15 eggs. 2) Chance of pregnancy with 8-12 eggs is ~40-50% but depends on the number of eggs frozen and the age of the patient at the time of freezing. 3) Approximately only 5-10% of patients will return to use the frozen oocytes.¹⁵⁻¹⁷
Fertility Preservation for Individuals Assigned Male at Birth (AMAB) with Sperm Cryopreservation	1) Some patients may undergo the procedure and be able to conceive naturally later in life. 2) Associated financial costs. 3) Long term storage issues, risk of storage failure, and ethical considerations if the patient passes away. 4) Social discomfort in some cases with discussing sperm cryopreservation.	1) Option to potentially preserve fertility in cases of impairment. 2) Self-reassurance if successful sperm banked	1) It is estimated >95% of patient who pursue fertility preservation counseling will attempt semen sample. 2) About 90-95% will be successful in producing a viable sample. 3) 15% of these patients are estimated to use cryopreserved sperm for fertility treatment. 4) The success rate depends on the type of fertility treatment (IVF or IUI) and the age of the AFAB partner.¹⁸⁻²⁰

Appendix E - Table 1: Cyclophosphamide Equivalent Dosing

Cyclophosphamide Equivalent Dosing (CED) calculation*	
Agent dose mg/m2 (CED)	Correction factor
Cyclophosphamide	1.0
Ifosfamide	0.244
Procarbazine	0.857
Chlorambucil	14.286
BCNU (Carmustine)	15
CCNU (Lomustine)	16
Melphalan	40
Thiotepa	50
Nitrogen Mustard	100
Busulphan	8.823


Appendix F - Table 2: Risk of Infertility for Individuals Assigned Female at Birth


CED equivalent (mg/m ²) ⁸	Individual Assigned Female at Birth
<4,000	Low (<20%)
4000 - 8000	Intermediate (20-80%)
>8000	High (>80%)
Radiation Exposure ^{13,21}	
Total Body	High
Whole abdomen or pelvic radiation ≥15Gy pre-pubertal <u>or</u> ≥10 Gy post-pubertal 10 to < 15 Gy pre-pubertal (5 to <10 Gy post-pubertal)	High Intermediate
Cranial >30 Gy Cranial <30 Gy	High Low/Intermediate
Spinal irradiation 24-36 Gy 18-24 Gy	High Intermediate
Other ¹³	
Conditioning for Transplant (e.g. Cyclophosphamide, Busulfan, Melphalan)	High
Radioactive iodine	None
Bevacizumab	Intermediate
Cisplatin	Low/Intermediate

Appendix G - Table 3: Risk of Infertility for Individuals Assigned Male at Birth

CED equivalent (mg/m²)⁸	Individual Assigned Male at Birth
<4,000	Low (<20%)
>4000	High (>80%)
Radiation Exposure	
Total Body	High
Testicular or Pelvic >6 Gy	High
Testicular or Pelvic <6 Gy	Low/Intermediate
Cranial >30 Gy	High
Cranial <30 Gy	Low/Intermediate
Spinal irradiation 24-36 Gy	High
Other	
Conditioning for Transplant (e.g. Cyclophosphamide, Busulfan, Melphalan)	High
Cisplatin cumulative >400 mg/m ²	Intermediate
Carboplatin dose >2g/m ²	Intermediate
Radioactive iodine	Low
Bevacizumab	Low

Appendix H - Fertility Care Outline for Individuals Assigned Female at Birth





Appendix I - Fertility Care Outline for Individuals Assigned Male at Birth

